This is not the most recent version of the article. View current version (22 APR 2015)

Intervention Protocol

You have free access to this content

Dimethyl fumarate for multiple sclerosis

  1. Zhu Xu1,
  2. Feng Zhang2,
  3. FangLi Sun3,
  4. KeFeng Gu4,
  5. Shuai Dong2,
  6. Dian He1,*

Editorial Group: Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group

Published Online: 18 APR 2014

Assessed as up-to-date: 24 JAN 2014

DOI: 10.1002/14651858.CD011076


How to Cite

Xu Z, Zhang F, Sun F, Gu K, Dong S, He D. Dimethyl fumarate for multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2014, Issue 4. Art. No.: CD011076. DOI: 10.1002/14651858.CD011076.

Author Information

  1. 1

    Affiliated Hospital of Guiyang Medical College, Department of Neurology, Guiyang, Guizhou Procince, China

  2. 2

    Jinan No. 6 People's Hospital, Department of Neurology, Jinan, Shandong Province, China

  3. 3

    Jinan No. 6 People's Hospital, Department of Medical Imaging, Jinan, Shandong Province, China

  4. 4

    Jinan No. 6 People's Hospital, Department of Interventional Radiology, Jinan, Shandong Province, China

*Dian He, Department of Neurology, Affiliated Hospital of Guiyang Medical College, No. 28, Gui Yi Street, Guiyang, Guizhou Procince, 550004, China. ileks@163.com.

Publication History

  1. Publication Status: New
  2. Published Online: 18 APR 2014

SEARCH

This is not the most recent version of the article. View current version (22 APR 2015)

References

Additional references

Albrecht 2012
  • Albrecht P, Bouchachia I, Goebels N, Henke N, Hofstetter HH, Issberner A, et al. Effects of dimethyl fumarate on neuroprotection and immunomodulation. Journal of Neuroinflammation 2012;9:163.
Bar-Or 2013
  • Bar-Or A, Gold R, Kappos L, Arnold DL, Giovannoni G, Selmaj K, et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. Journal of Neurology 2013;260(9):2297-305.
Cella 1996
Confavreux 2006
Filippini 2013
Fischer 1999
Fox 2012
  • Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. The New England Journal of Medicine 2012;367(12):1087-97.
Ghoreschi 2011
  • Ghoreschi K, Brück J, Kellerer C, Deng C, Peng H, Rothfuss O, et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. Journal of Experimental Medicine 2011;208(11):2291-303.
Gilgun-Sherki 2004
Gold 2012
  • Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. The New England Journal of Medicine 2012;367(12):1098-107.
GRADEpro 2008
  • Brozek J, Oxman A, Schünemann H. GRADEpro. 3.2 for Windows. Brozek J, Oxman A, Schünemann H, 2008.
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Hutchinson 2013
  • Hutchinson M, Fox RJ, Miller DH, Phillips JT, Kita M, Havrdova E, et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. Journal of Neurology 2013;260(9):2286-96.
Hutchinson 2014
  • Hutchinson M, Fox RJ, Havrdova E, Kurukulasuriya NC, Sarda SP, Agarwal S, et al. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Current Medical Research Opinion 2014; Vol. 30, issue 4:613-27.
Johnson 2010
  • Johnson DA, Amirahmadi S, Ward C, Fabry Z, Johnson JA. The absence of the pro-antioxidant transcription factor Nrf2 exacerbates experimental autoimmune encephalomyelitis. Toxicological Sciences 2010;114(2):237-46.
Kappos 2008
  • Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008;372(9648):1463-72.
Kappos 2012
  • Kappos L, Gold R, Miller DH, MacManus DG, Havrdova E, Limmroth V, et al. Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study. Multiple Sclerosis 2012;18(3):314-21.
Kappos 2014
  • Kappos L, Gold R, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: The DEFINE study. Multiple Sclerosis 2014; Vol. 20, issue 2:243-52.
Karampampa 2012a
  • Karampampa K, Gustavsson A, Miltenburger C, Eckert B. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries. Multiple Sclerosis 2012;18(2 Suppl):7-15.
Karampampa 2012b
  • Karampampa K, Gustavsson A, Miltenburger C, Kindundu CM, Selchen DH. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada. Journal of Population Therapeutics and Clinical Pharmacology 2012;19(1):11-25.
Karampampa 2013
  • Karampampa K, Gustavsson A, van Munster ET, Hupperts RM, Sanders EA, Mostert J, et al. Treatment experience, burden, and unmet needs (TRIBUNE) in Multiple Sclerosis study: the costs and utilities of MS patients in The Netherlands. Journal of Medical Economics 2013;16(7):939-50.
Kita 2014
  • Kita M, Fox RJ, Phillips JT, Hutchinson M, Havrdova E, Sarda SP, et al. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. Multiple Sclerosis 2014; Vol. 20, issue 2:253-7.
Kurtzke 1983
Lee 2008
  • Lee DH, Linker RA, Gold R. Spotlight on fumarates. International MS Journal 2008;15(1):12-8.
Lee 2012
  • Lee DH, Gold R, Linker RA. Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters. International Journal of Molecular Sciences 2012;13(9):11783-803.
Linker 2011
  • Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, Bista P, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011;134(3):678-92.
Litjens 2004
Lublin 1996
  • Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-11.
Lukashev 2007
  • Lukashev M, Zeng W, Goelz S, Lee D, Linker R, Gold R, et al. Activation of Nrf2 and modulation of disease progression in EAE models by BG00012 (dimethyl fumarate) suggests a novel mechanism of action combining anti-inflammatory and neuroprotective modalities. Multiple Sclerosis 2007;13(Suppl 2):149.
MacManus 2011
  • MacManus DG, Miller DH, Kappos L, Gold R, Havrdova E, Limmroth V, et al. BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. Journal of Neurology 2011;258(3):449-56.
McDonald 2001
Oleen-Burkey 2012
Peng 2012
  • Peng H, Guerau-de-Arellano M, Mehta VB, Yang Y, Huss DJ, Papenfuss TL, et al. Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling. Journal of Biological Chemistry 2012;287(33):28017-26.
Polman 2005
Polman 2011
Poser 1983
Review Manager 2012
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Scannevin 2012
  • Scannevin RH, Chollate S, Jung MY, Shackett M, Patel H, Bista P, et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. Journal of Pharmacology and Experimental Therapeutics 2012;341(1):274-84.
Schilling 2006
Schimrigk 2006
Shirani 2012
  • Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012;308(3):247-56.
Tullman 2004
Vickrey 1995
Ware 1992
Wilms 2010
  • Wilms H, Sievers J, Rickert U, Rostami-Yazdi M, Mrowietz U, Lucius R. Dimethyl fumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation. Journal of Neuroinflammation 2010;7:30.